No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Chart series for revenue are being prepared.
No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Chart series for revenue are being prepared.
The latest delayed quote for Obsidian Therapeutics Inc. (OBX) stock was $13.22 as of Oct 6, 2026, 4:00 PM EDT, down 4.48% from the previous close.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Biotechnology · Cambridge, MA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-1.19
vs Estimate
$-1.64
Revenue
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1OBX | $13.75M | $13.22 | -4.48% | N/A | N/A | N/A | N/A |
| 2SINT | $13.86M | $2.18 | +0.00% | N/A | N/A | N/A | vs OBX |
| 3PLSM | $14.05M | $2.16 | -2.26% | N/A | N/A | N/A | vs OBX |
| 4INAB | $13.33M | $1.39 | -2.11% | -40.44% | -62.88% | N/A | vs OBX |
| 5OPTH | $13.30M | $4.13 | -3.84% | -49.89% | -21.80% | N/A | vs OBX |
| 6CTXR | $13.20M | $0.48 | -7.56% | -61.87% | -60.04% | -46.34% | vs OBX |
forward FY estimate
N/A
vs Estimate
N/A
Consensus Rating
Based on 3 analysts
Average Price Target
$39.00
+195.0% upside
Low
$32.00
Current
$13.22
High
$43.00